{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:53:26Z","timestamp":1770836006491,"version":"3.50.1"},"reference-count":0,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[1993,4,1]],"date-time":"1993-04-01T00:00:00Z","timestamp":733622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1993,4]]},"abstract":"<jats:p>We have tested the in vitro activities of streptomycin, rifampin, tetracyclines, trimethoprim-sulfamethoxazole, erythromycin, four new macrolides (roxithromycin, azithromycin, clarithromycin, and dirithromycin), and rifapentine against 62 strains of Brucella spp. Azithromycin and clarithromycin were, respectively, eight- and twofold more active than erythromycins (MIC for 90% of strains = 2, 8, and 16 micrograms\/ml, respectively). The activity of rifapentine was similar to that of rifampin (MIC for 90% of strains = 1 microgram\/ml).<\/jats:p>","DOI":"10.1128\/aac.37.4.911","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T00:05:50Z","timestamp":1340841950000},"page":"911-913","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":28,"title":["In vitro activities of new macrolides and rifapentine against Brucella spp"],"prefix":"10.1128","volume":"37","author":[{"given":"J A","family":"Garc\u00eda-Rodr\u00edguez","sequence":"first","affiliation":[{"name":"Department of Microbiology, Hospital Cl\u00ednico Universitario, Salamanca, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J L","family":"Mu\u00f1oz Bellido","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Hospital Cl\u00ednico Universitario, Salamanca, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M J","family":"Fresnadillo","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Hospital Cl\u00ednico Universitario, Salamanca, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Trujillano","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Hospital Cl\u00ednico Universitario, Salamanca, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.37.4.911","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.37.4.911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:34:24Z","timestamp":1645457664000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.37.4.911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,4]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1993,4]]}},"alternative-id":["10.1128\/AAC.37.4.911"],"URL":"https:\/\/doi.org\/10.1128\/aac.37.4.911","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,4]]},"assertion":[{"value":"1993-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}